(July 21, 2023, 10:28 AM EDT) -- ALEXANDRIA, Va. — A petitioner for inter partes review (IPR) has demonstrated that it will likely succeed in establishing that at least one challenged claim of a patent directed to a pharmaceutical composition cytidine analog should be canceled, the Patent Trial and Appeal Board revealed July 20....